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a b s t r a c t
INTRODUCTION: Primary hyperparathyroidism is a common endocrine disorder for which the primary
treatment is surgery. For minimal invasive parathyroidectomy adequate pre-operative imaging is essen-
tial. Conventional imaging is often inconclusive. There are reports that 18F-ﬂuorocholine PET–CT might
be a superior imaging modality, however evidence is still very scarce. This is the ﬁrst report of a case
with negative ultrasound and sestamibi SPECT–CT imaging that underwent successful minimal invasive
surgery because of 18F-ﬂuorocholine PET–CT.
PRESENTATION OF CASE: A 57 year-oldman presented to us with complaints of fatigue. Laboratory results
showedabiochemical primaryhyperparathyroidismandan additionalDEXA-scan revealed osteopenia of
the lumbar spine. Conventional imaging consisting of neck ultrasound and Tc-99m-sestamibi SPECT–CT
was however unable to localize the pathological gland. Subsequent 18F-ﬂuorocholine PET–CT did clearly
localize an adenoma dorsally of the left thyroid lobe which was removed at that exact location using
minimal invasive parathyroidectomy. Histological examination conﬁrmed the diagnosis adenoma and
calcium levels remained normal at follow-up.
DISCUSSION: There is clinical need for a superior imaging modality to detect pathological parathyroid
glands to enable minimal invasive surgery. 18F-Fluorocholine is widely available.
CONCLUSION: 18F-Fluorocholine PET–CT is a promising new imaging modality for localizing parathyroid
adenomas and enabling minimal invasive parathyroidectomy when conventional imaging fails to do.
Clinicians should consider its use as a second line modality for optimal patient care.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Primary hyperparathyroidism (pHPT) is characterized by
autonomous hypersecretion of parathyroid hormone (PTH) by one
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sound.
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or more parathyroid glands, leading to an elevated serum cal-
cium concentration. Hypercalcemia can cause a wide variety of
well-described symptoms ranging from constipation and nausea
to kidney stones and osteoporosis [1]. Diagnosis is established bio-
chemically, with the ﬁnding of a relatively elevated serum calcium
(Ca) levelwith a concomitant inappropriately elevated PTH level. In
over 80% of cases, pHPT is caused by a single parathyroid adenoma
[2]. Although both medical and surgical options for treatment are
available, surgery is currently the only method of deﬁnitive cure as
well as the most effective treatment modality overall [3].
The method of surgical intervention has shifted over the past
two decades from extensive bilateral neck exploration (BNE)
to minimal invasive parathyroidectomy (MIP). Minimal invasive
surgery has its attendant beneﬁts to shorter operative time, lower
complication rate, and smaller incision length [4–6]. For surgery
to be successful, adequate pre-operative imaging is essential to
localize the abnormal gland(s). Conventional imaging consists
http://dx.doi.org/10.1016/j.ijscr.2015.06.012
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Coronal maximum intensity projection (MIP) of negative 99mTc-sestamibi SPECT and axial SPECT–CT (1a). Coronal MIP and axial PET–CT (1b) performed with 18F-
ﬂuorocholine clearly show a hotspot located posterior to the left upper thyroid lobe.
of ultrasound (US) and Tc-99-sestamibi scanning. However even
the most sensitive sestamibi scan, single photon emission com-
puted tomography (SPECT)—computed tomography (CT), fails to
identify abnormal parathyroid glands in up to 30% of cases [7].
These cases mandate traditional BNE or treatment with cal-
cimimetics. Recently, a case report was published describing a
potential new imagingmodality for patients with pHPT. Quak et al.
reported the incidental ﬁnding of a parathyroid adenomausing 18F-
ﬂuorocholine (FCH) positron emission tomography (PET)–CT in a
patient suspected of recurrence of prostate cancer [8]. Choline is
part of thephospholipid layer in thecellmembraneand it ishypoth-
esized that hyperfunctioning parathyroid cells have an increased
activity of the phospholipid/Ca2+-dependent protein kinase which
would lead to increased choline uptake [9]. Since then two studies
with preliminary results have been published showing a superior
detecting rate of FCH PET–CT over different types of conventional
imaging [10,11]. We present, to our knowledge, the ﬁrst case with
negative US and SPECT–CT who underwent a successful MIP based
on FCH PET–CT.
2. Case report
A57-year-oldmanwas referred to theDepartment of Surgery in
February 2013 with complaints of fatigue. Biochemical laboratory
investigation revealed pHPT. Laboratory results showed slightly
elevated levels of Ca 2.78mmol/L (normal: 2.20–2.60mmol/L) and
PTH of 10pmol/L (normal: 1–7pmol/L). Albumin level was 47.4 g/L
(normal: 35–50g/L) and 25-OH-vitamin-Dwas 67nmol/L (normal:
50–100nmol/L). Additional DEXA scanning showed osteopenia
of the lumbar spine and it was decided that surgery was
indicated. Conventional pre-operative imaging studies (US and
99mTc-sestamibi SPECT–CT (Fig. 1a)) did not reveal a parathy-
roid adenoma. Calcimimetics were prescribed, but serum Ca levels
remained elevated. Subsequently a FCH PET–CT of the neck and
mediastinumwasperformed30minafter injectionof 171MBqFCH.
PET–CT showed intense focal FCH accumulation in a hypodense
lesion posterior to the left upper thyroid lobe (Fig. 1b). Subse-
quently targeted US was performed and the parathyroid adenoma
was visualized and marked for a MIP.
During surgery an abnormal gland was removed at the
exact location indicated by FCH PET–CT. Histological examination
showed a gland of 0.59g and the diagnosis parathyroid adenoma
was conﬁrmed. Post-operatively Ca levels normalized and the
patient remains normocalcemic at follow-up.
3. Discussion
Our patient had pHPT with an indication for surgery, however
conventional imaging studies were unable to localize the patho-
logical gland. This can be the case in up to 30% of patients and
does not even take into account cases in which one study is dis-
cordant with another. Clinicians face a dilemma in all of these
cases; they can either choose to perform a traditional BNE with
greater morbidity or repeat the imaging after 6 months. In the
meantime, the patient can be placed on medical therapy such as
calcimimetics. Treatment with calcimimetics however, is not cura-
tive and often causes signiﬁcant side effects including nausea and
vomiting [12]. Both waiting and performing a BNE may, there-
fore, prove to be suboptimal for the patient. We propose that FCH
PET–CT might be a solution whenever conventional imaging is
unrevealing or discordant. So far two studies have published pre-
liminary results. Michaud et al. investigated 12 patients with both
primary and secondaryHPT andnegative or equivocal conventional
imaging studies [10]. Their conventional imaging consisted of US
and 123I/99mTc-sestamibi subtraction scintigraphy. They found an
excellent parathyroid detection rate of 92% for FCH PET–CT. Lezaic
et al. included 24 patients with HPT and performed three types
of sestamibi scanning next to the FCH PET–CT [11]. They found a
sensitivity of 92% for FCH PET–CT, which was signiﬁcantly higher
compared to the sestamibi scans. The advantage of FCH PET–CT
over SPECT–CT is the higher spatial resolution and the signifcantly
shorter scanning time with a single acquisition of only 8min. The
disadvantage of this modality is the high cost compared to conven-
tional modalities and therefore an option would be to preserve it
for the caseswithnegative/discordant imaging. At thismoment, the
combination of US and SPECT–CT is considered to bemost accurate
in the case of pHPT and is commonly used worldwide [13,14]. Our
case is, to our knowledge, the ﬁrst in which both US and SPECT–CT
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were negative but that could be operated on successfully by mini-
mally invasive approach thanks to FCH PET–CT.
4. Conclusions
In conclusion, pHPT is a common disorder for which the pri-
mary treatment of choice is MIP. For MIP adequate pre-operative
imaging is needed. FCH PET–CT is a promising new second line
imaging modality that can guide succesfull MIP in the case of neg-
ative SPECT–CT and US.
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